SCHEMBL1834147

SCHEMBL1834147

CCNCCN(CC)C(C)=O

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PAOX Q6QHF9 1/20 0.34
CYP2C19 P33261 2/20 0.33
ALDH1A1 P00352 1/20 0.33
ALDH2 P05091 1/20 0.33
LMNA P02545 1/20 0.33
MEN1 O00255 1/20 0.33
GLA P06280 1/20 0.33
KMT2A Q03164 1/20 0.33
CA12 O43570 1/20 0.32
CA1 P00915 1/20 0.32
CA9 Q16790 1/20 0.32
MMP1 P03956 1/20 0.32
MMP2 P08253 1/20 0.32
MMP3 P08254 1/20 0.32
MMP8 P22894 1/20 0.32
CYP1A2 P05177 1/20 0.32
TSHR P16473 1/20 0.32
KDM5B Q9UGL1 1/20 0.31
HDAC3 O15379 1/20 0.30
HDAC4 P56524 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1829814 0.88 PAOX (0.43) PAOXCYP2C19LMNAMEN1GLA
SCHEMBL9170356 0.83 ALDH1A1 (0.37) PAOXCYP2C19ALDH1A1ALDH2LMNA
SCHEMBL12444629 0.83 LMNA (0.38) PAOXCYP2C19ALDH1A1ALDH2LMNA
SCHEMBL1450227 0.80 PAOX (0.31) PAOXALDH1A1ALDH2
SCHEMBL1832441 0.80 PRMT3 (0.39) PAOXALDH1A1ALDH2LMNACA12
SCHEMBL1835807 0.79 ZDHHC20 (0.37) CYP1A2
SCHEMBL24554276 0.78 ALOX15 (0.39) PAOXALDH1A1ALDH2LMNACA12
SCHEMBL9287610 0.78 KDM4E (0.44) PAOXALDH1A1TSHR
SCHEMBL135270 0.78 GAA (0.33) CYP2C19ALDH1A1ALDH2LMNAMEN1
SCHEMBL15616382 0.77 LMNA (0.36) ALDH1A1ALDH2LMNAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3331880-B3 N-(PYRIDIN-2-YL)-4-(THIAZOL-5-YL)PYRIMIDIN-2-AMINE DERIVATIVES AS THERAPEUTIC COMPOUNDS AUCENTRA THERAPEUTICS PTY LTD (AU) 2023-01-11 EP disclosed
US-20130005696-A1 BUFADIENOLIDE DERIVATIVES, PREPARING PROCESS THEREOF, COMPOSITION COMPRISING THE SAME AND THE USE THEREOF SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) 2013-01-03 US disclosed
EP-2323144-A1 Electrolytic capacitor MITSUBISHI CHEMICAL CORPORATION (JP) 2011-05-18 EP disclosed
EP-2323145-A1 Electrolytic solution for electrolytic capacitor and electrolytic capacitor as well as method for preparing an organic onium tetrafluoroaluminate MITSUBISHI CHEMICAL CORPORATION (JP) 2011-05-18 EP disclosed
CN-100466122-C Electrolytic solution for electrolytic capacitor, and method for producing tetrafluoroaluminate salt of organic onium MITSUBISHI CHEM CORP (JP) 2009-03-04 CN disclosed
US-7397651-B2 Electrolyte for electrolytic capacitor, electrolytic capacitor and process for producing tetrafluoroaluminate salt of organic onium MITSUBISHI CHEMICAL CORPORATION (JP) 2008-07-08 US disclosed
US-7295424-B2 Electrolyte for electrolytic capacitor, electrolytic capacitor and process for producing tetrafluoroaluminate salt of organic onium MITSUBISHI CHEMICAL CORPORATION (JP) 2007-11-13 US disclosed
US-20070188979-A1 ELECTROLYTE FOR ELECTROLYTIC CAPACITOR, ELECTROLYTIC CAPACITOR AND PROCESS FOR PRODUCING TETRAFLUOROALUMINATE SALT OF ORGANIC ONIUM MITSUBISHI CHEMICAL CORPORATION (JP) 2007-08-16 US disclosed
US-20070188977-A1 ELECTROLYTE FOR ELECTROLYTIC CAPACITOR, ELECTROLYTIC CAPACITOR AND PROCESS FOR PRODUCING TETRAFLUOROALUMINATE SALT OF ORGANIC ONIUM MITSUBISHI CHEMICAL CORPORATION (JP) 2007-08-16 US disclosed
US-7227738-B2 Electrolyte for electrolytic capacitor, electrolytic capacitor and process for producing tetrafluoroaluminate salt of organic onium MITSUBISHI CHEMICAL CORPORATION (JP) 2007-06-05 US disclosed
US-20060007629-A1 Electrolyte for electrolytic capacitor, electrolytic capacitor and process for producing tetrafluoroaluminate salt of organic onium MITSUBISHI CHEMICAL CORPORATION (JP) 2006-01-12 US disclosed
CN-1708817-A Electrolytic solution for electrolytic capacitor, and method for producing tetrafluoroaluminate salt of organic onium MITSUBISHI CHEM CORP (JP) 2005-12-14 CN disclosed
EP-1564768-A1 ELECTROLYTE FOR ELECTROLYTIC CAPACITOR, ELECTROLYTIC CAPACITOR AND PROCESS FOR PRODUCING TETRAFLUOROALUMINATE SALT OF ORGANIC ONIUM Mitsubishi Chemical Corporation (JP) 2005-08-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130005696-A1 BUFADIENOLIDE DERIVATIVES, PREPARING PROCESS THEREOF, COMPOSITION COMPRISING THE SAME AND THE USE THEREOF CYP11B1, CYP51A1, U2AF1 PAOX 1307/4885CYP2C19 47/4885ALDH1A1 731/4885
US-20070188977-A1 ELECTROLYTE FOR ELECTROLYTIC CAPACITOR, ELECTROLYTIC CAPACITOR AND PROCESS FOR PRODUCING TETRAFLUOROALUMINATE SALT OF ORGANIC ONIUM AFF2, CACNA2D2, AFF4 PAOX 3467/4885CYP2C19 4595/4885ALDH1A1 3484/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.